Research and treatment approaches to depression
The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Depression is a major cause of disability worldwide, but we know little about the underlying fundamental biology. Research is hindered by the difficulties of modelling a disorder of higher cognitive functions in animals. Depression can be understood as the interaction of genetic susceptibility and environmental factors; however, current classifications are purely descriptive. The complexity of this field is best approached by rigorous explorations of known candidate systems in conjunction with the use of genomic tools to discover new targets for antidepressants and to predict therapeutic outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies using PET imaging 87 as well as analyses of post-mortem brain tissue 88 have indicated neuroinflammation and microglial activation in the central nervous systems of patients with MDD.”
From Major depressive disorder (2016) · cites this paper as [87]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Learned helplessness in humans: Critique and reformulation.
Abramson, L. Y., Seligman, M. E., & Teasdale, J. D. (1978) · Journal of Abnormal Psychology · doi:10.1037//0021-843x.87.1.49 · Cited by 7,121
(1996) · Cited by 6,884
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162 · cited 1×
“have identified a functional polymorphism in the upstream regulatory region of the serotonin transporter gene that affects transcriptional efficienc”
BackgroundA Syndrome produced by Diverse Nocuous Agents
SELYE, H. (1936) · Nature · doi:10.1038/138032a0 · Cited by 3,903
Genetic Epidemiology of Major Depression: Review and Meta-Analysis
Sullivan, P. F., Neale, M. C., & Kendler, K. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.10.1552 · Cited by 3,431 · cited 1×
“Major depression has an estimated heritability of 31–42%, which is much lower than the 70% heritability estimated for schizophrenia and bipolar disorde”
BackgroundGenetic Dissection of Complex Traits
Lander, E. S., & Schork, N. J. (1994) · Science · doi:10.1126/science.8091226 · Cited by 3,413
The Concepts of Stress and Stress System Disorders: Overview of Physical and Behavioral Homeostasis
Chrousos, G. P. (1992) · JAMA · doi:10.1001/jama.1992.03480090092034 · Cited by 2,689
Cross-national epidemiology of major depression and bipolar disorder
Weissman, M. M. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540040037030 · Cited by 2,302 · cited 1×
“A detailed and well-controlled cross-national epidemiological study examined lifetime rates of depression in ten countrie”
BackgroundExcess mortality of mental disorder
Harris, C., & Barraclough, B. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.1.11 · Cited by 1,881 · cited 1×
“Depressed patients have an increased risk of premature death when compared with control subject”
Background
Research works printed but not linked: 1
- Nobel Foundation. Nobel Lectures — Physiology or Medicine, 1901–1970 (Elsevier, Amsterdam, 1970).
Cited by
Items 101–200 of 674
David, D. J., Wang, J., Samuels, B. A., Rainer, Q., David, I., Gardier, A. M., & Hen, R. (2010) · The Neuroscientist · doi:10.1177/1073858409360281 · Cited by 108
“Like the first-generation antidepressants, SSRIs require at least 4 to 6 weeks before achieving therapeutic benefits (Wong and Licinio 2001).”
BackgroundAlboni, S., Poggini, S., Garofalo, S., Milior, G., El Hajj, H., Lecours, C., Girard, I., Gagnon, S., Boisjoly-Villeneuve, S., Brunello, N., et al. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.155 · Cited by 111
“Accordingly, the quality of the environment has been shown to determine the outcome of SSRI treatment on the vulnerability to obesity (Mastronardi et al., 2011; Wong and Licinio, 2001).”
Baeken, C., & De Raedt, R. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/cbaeken · Cited by 108
“Furthermore, the underlying pathophysiological mechanisms of this affective disorder are still under debate.(4) In spite of these neurobiological uncertainties, we are in need of alternative treatment options.”
PKA-CREB-BDNF signaling regulated long lasting antidepressant activities of Yueju but not ketamine
Xue, W., Wang, W., Gong, T., Zhang, H., Tao, W., Xue, L., Sun, Y., Wang, F., & Chen, G. (2016) · Scientific Reports · doi:10.1038/srep26331 · Cited by 112
“In contrast, H-89 couldn’t block the antidepressant-like effect of ketamine: a two-way ANOVA revealed the significant main effect of ketamine treatment (F(1,28) = 45.”
BackgroundMethodInfluentialKwon, S., Lee, B., Kim, M., Lee, H., Park, H., & Hahm, D. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.11.015 · Cited by 118
Freitas, A. E., Egea, J., Buendía, I., Gómez‐Rangel, V., Parada, E., Navarro, E., Casas, A. I., Wojnicz, A., Ortiz, J. A., Cuadrado, A., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9182-6 · Cited by 116
“In the present study, female mice were chosen because more women than men suffer depression [34, 35].”
BackgroundRelevance of endogenous 3α-reduced neurosteroids to depression and antidepressant action
Uzunova, V., Sampson, L., & Uzunov, D. P. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0201-6 · Cited by 119
“Depression is a serious widespread psychiatric disorder and is a leading cause of disability worldwide, with an estimated lifetime prevalenceofas highas21.3%inwomen and 12.7% in men in the USA ( Wong and Licinio 2001, 2004 ).”
BackgroundInfluentialAntidepressant‐like activity of gallic acid in mice subjected to unpredictable chronic mild stress
Chhillar, R., & Dhingra, D. (2012) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2012.01040.x · Cited by 112
Current investigational drugs for major depression
Kulkarni, S. K., & Dhir, A. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902880850 · Cited by 122
“Major depression represents one of the most common and proliferating health problems worldwide [1,2].”
BackgroundAntidépresseurs et tolérance : déterminants et prise en charge des principaux effets indésirables
David, D. J., & Gourion, D. (2016) · L'Encéphale · doi:10.1016/j.encep.2016.05.006 · Cited by 105
Hashimoto, H., Hashimoto, R., Shintani, N., Tanaka, K., Yamamoto, A., Hatanaka, M., Guo, X., Morita, Y., Tanida, M., Nagai, K., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06168.x · Cited by 108
The impact of HF-rTMS treatment on serotonin2A receptors in unipolar melancholic depression
Baeken, C., De Raedt, R., Bossuyt, A., Van Hove, C., Mertens, J., Dobbeleir, A., Blanckaert, P., & Goethals, I. (2011) · Brain Stimulation · doi:10.1016/j.brs.2010.09.002 · Cited by 101
Son, H., Banasr, M., Choi, M., Chae, S. Y., Licznerski, P., Lee, B., Voleti, B., Li, N., Lepack, A., Fournier, N. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201191109 · Cited by 103
“M depressive disorder (MDD) is a devastating and recurrent illness affecting up to 17% of the population, resulting in personal disability, increased rates of suicide, and socioeconomic loss (1).”
BackgroundMolecular mechanism of noradrenaline during the stress-induced major depressive disorder
Jaiswal, M., Seki, K., & Yoshida, S. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.235019 · Cited by 95
Zeni, A. L. B., Zomkowski, A. D. E., Maraschin, M., Rodrigues, A. L. S., & Tasca, C. I. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.12.041 · Cited by 107
Gur, T. L., Conti, A. C., Holden, J., Bechtholt, A. J., Hill, T. E., Lucki, I., Malberg, J. E., & Blendy, J. A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2051-07.2007 · Cited by 101
“Antidepressant (AD) treatment involves amelioration of symptoms over the course of weeks or months (Wong and Licinio, 2001).”
BackgroundDavid, D. J. P., & Gardier, A. M. (2016) · L Encéphale · doi:10.1016/j.encep.2016.03.012 · Cited by 118
The olfactory bulbectomized rat as a model of depression: The hippocampal pathway
Morales‐Medina, J. C., Iannitti, T., Freeman, A. R., & Caldwell, H. K. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.09.029 · Cited by 103
Neuronal nitric oxide synthase and affective disorders
Zhou, Q., Zhu, X., Nemes, A. D., & Zhu, D. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.11.004 · Cited by 106
Hattori, S., Hashimoto, R., Miyakawa, T., Yamanaka, H., Maeno, H., Wada, K., & Kunugi, H. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.02.036 · Cited by 107
Systemic interferon-α regulates interferon-stimulated genes in the central nervous system
Wang, J., Campbell, I. L., & Zhang, H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002013 · Cited by 108
Machado, D. G., Cunha, M. P., Neis, V. B., Balen, G. O., Colla, A. R. D. S., Grando, J., Brocardo, P. S., Bettio, L. E. B., Capra, J. C., & Rodrigues, A. L. S. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.08.024 · Cited by 111
Lack of promoter IV‐driven BDNF transcription results in depression‐like behavior
Sakata, K., Jin, L., & Jha, S. (2010) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2010.00605.x · Cited by 94
“…depression, knock-in, promoter IV, mice Received 3 February 2010, revised 9 April 2010 and 19 May 2010, accepted for publication 20 May 2010 Major depressive disorder (MDD) is a leading cause of disease burden characterized by a general loss of interest and by anhedonia (Wong & Licinio 2001).”
BackgroundAdult Human Neurogenesis: From Microscopy to Magnetic Resonance Imaging
Sierra, A., Encinas, J. M., & Maletic-Savatic, M. (2011) · Frontiers in Neuroscience · doi:10.3389/fnins.2011.00047 · Cited by 91
“This hypothesis is strongly supported by the ability of antidepressant drugs, such as selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants (TCAs), to improve the symptomatology by increasing synaptic levels of monoamines (Wong and Licinio, 2001).”
BackgroundInfluentialComparison of neurogenic effects of fluoxetine, duloxetine and running in mice
Marlatt, M. W., Lucassen, P. J., & van Praag, H. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.086 · Cited by 96
Dettling, A. C., Feldon, J., & Pryce, C. R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00785-2 · Cited by 95
Vizi, E. S., Zsilla, G., Caron, M. G., & Kiss, J. P. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1506-04.2004 · Cited by 92
“According to the monoamine theory, the neurochemical background of depression is an impairment of noradrenergic and/or serotonergic neurotransmission and the concomitant decrease of biophase concentration of these transmitters (Hindmarch, 2001; Wong and Licinio, 2001).”
BackgroundZomkowski, A. D. E., Engel, D., Gabilan, N. H., & Rodrigues, A. L. S. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.07.011 · Cited by 94
“It is important to note that this study was performed in female mice, since several studies have shown that the prevalence of depression is about two fold higher in women than in men (Wong and Licinio, 2001).”
BackgroundMales and females respond differently to controllability and antidepressant treatment
Leuner, B., Mendolia‐Loffredo, S., & Shors, T. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.09.018 · Cited by 99
5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials
Pithadia, A. B., & Jain, S. (2009) · Journal of Clinical Medicine Research · doi:10.4021/jocmr2009.05.1237 · Cited by 94
“, fluoxetine, fluoxamine, paroxetine, citalopram and sertraline are effective as tricyclic anti-depressants (TCAs) and MAO-I (monoamine oxidase inhibitors) in treating depression of moderate degree but probably less effective than TCAs in treating severe depression [5].”
BackgroundHuang, X., Fei, G., Liu, W., Ding, J., Wang, Y., Wang, H., Jian-lin, J., & Wang, X. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0317-6 · Cited by 93
Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise
Moon, H. Y., Kim, S. H., Yang, Y. R., Song, P., Yu, H. S., Park, H. G., Hwang, O., Lee-Kwon, W., Seo, J. K., Hwang, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205535109 · Cited by 95
“Although numerous antidepressant drugs have been introduced, limits remain in both their degree of therapeutic efficacy and our understanding of their underlying mechanisms (2, 3).”
BackgroundThe Ups and Downs of Modelling Mood Disorders in Rodents
Slattery, D. A., & Cryan, J. F. (2014) · ILAR Journal · doi:10.1093/ilar/ilu026 · Cited by 85
Denny, S., Clark, T. C., Fleming, T., & Wall, M. (2004) · American Journal of Orthopsychiatry · doi:10.1037/0002-9432.74.2.137 · Cited by 88
Ebrahim, I. O., Howard, R., Kopelman, M. D., Sharief, M. K., & Williams, A. J. (2002) · Journal of the Royal Society of Medicine · doi:10.1177/014107680209500503 · Cited by 105
Quines, C. B., Rosa, S. G., da Rocha, J. T., Gai, B. M., Bortolatto, C. F., Duarte, M., & Nogueira, C. W. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.04.032 · Cited by 97
“Clinical studies indicate that the serotonergic system is strongly implicated in the etiology of these diseases, mostly accompanied with abnormalities in 5-HT neurotransmission (Hoyer et al., 2002; Wong and Licinio, 2001).”
BackgroundSzász, B. K., Mike, Á., Károly, R., Gerevich, Z., Illés, P., Vizi, E. S., & Kiss, J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.014 · Cited by 99
Imaging genetics of mood disorders
Scharinger, C., Rabl, U., Sitte, H. H., & Pezawas, L. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.02.019 · Cited by 84
“Since depression is highly heritable (Wong and Licinio, 2001), there has been intense interest in candidate genes related to this behavioral phenotype.”
BackgroundOver-inhibition: a model for developmental intellectual disability
Fernandez, F., & Garner, C. C. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.07.005 · Cited by 102
Lim, J.-E., Papp, A. C., Pinsonneault, J. K., Sadée, W., & Saffen, D. W. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001797 · Cited by 95
Stress-induced changes in primate prefrontal profiles of gene expression
Karssen, A. M., Her, S., Li, J. Z., Patel, P. D., Meng, F., Bunney, W. E., Jones, E. G., Watson, S. J., Akil, H., Myers, R., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002095 · Cited by 95
Posser, T., Kaster, M. P., Baraúna, S. C., Rocha, J. B. T., Rodrigues, A. L. S., & Leal, R. B. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.055 · Cited by 86
Guo, M., Lu, Y., Garza, J. C., Li, Y., Chua, S. C., Zhang, W., Lu, B., & Lu, X.-Y. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.9 · Cited by 83
Freitas, A. E., Budni, J., Lobato, K. R., Binfaré, R. W., Machado, D. G., Jacinto, J., Veronezi, P. O., Pizzolatti, M. G., & Rodrigues, A. L. S. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.12.010 · Cited by 88
Kiyohara, C., & Yoshimasu, K. (2010) · Psychiatric Genetics · doi:10.1097/ypg.0b013e328335112b · Cited by 79
“Environmental factors, such as prenatal factors, loss, deprivation, grief, stress, natural disasters, war, social support systems, nutrition, exercise, drug effects, and medical illness, have all been linked to MDD (Wong and Licinio, 2001).”
BackgroundEffects of Fish Oil on the Central Nervous System: A New Potential Antidepressant?
Naliwaiko, K., Araújo, R. L. F., da Fonseca, R. V., Castilho, J. C., Andreatini, R., Bellissimo, M. I., Oliveira, B. H., Martins, E. F., Curi, R., Fernandes, L. C., et al. (2004) · Nutritional Neuroscience · doi:10.1080/10284150410001704525 · Cited by 82
“western society with prevalence as high as 21% of the general population (Wong and Licinio, 2001).”
BackgroundSun, H.-L., Zhou, Z.-Q., Zhang, G.-F., Yang, C., Wang, X.-M., Shen, J.-C., Hashimoto, K., & Yang, J.-J. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.21 · Cited by 84
The pharmacological properties of antidepressants
Racagni, G., & Popoli, M. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283311acd · Cited by 83
“…adaptations (regulation of intracellular signal transduction pathways and expression of specific target genes) that underlie the therapeutic actions of antidepressants (Wong and Licinio, 2001; Nestler et al., 2002; Tardito et al., 2006; Krishnan and Nestler, 2008; Pittenger and Duman, 2008).”
BackgroundInfluentialThe antidepressant mechanism of action of vagus nerve stimulation: Evidence from preclinical studies
Grimonprez, A., Raedt, R., Baeken, C., Boon, P., & Vonck, K. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.06.019 · Cited by 81
Gu, P., Qian, W., Song, G., & Zhaochun, S. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.05.006 · Cited by 83
Eker, C., & Gonul, A. S. (2009) · World Journal of Biological Psychiatry · doi:10.1080/15622970902737998 · Cited by 64
Spadin as a new antidepressant: Absence of TREK-1-related side effects
Maati, H. M. O., Veyssière, J., Labbal, F., Coppola, T., Gandin, C., Widmann, C., Mazella, J., Heurteaux, C., & Borsotto, M. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.019 · Cited by 80
“Despite an important therapeutical arsenal, mainly with SSRI and NSRI drugs, more than one third of depression sufferers are resistant to treatments demonstrating the necessity to find new targets and new drugs for these patients (Wong and Licinio, 2001).”
BackgroundTouma, C., Fenzl, T., Ruschel, J., Palme, R., Holsboer, F., Kimura, M., & Landgraf, R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004325 · Cited by 77
“Another biological hallmark of MD is the dysregulation of the HPA axis (hyper- or hypo-activity), largely involving pathological alterations in the corticotrophin-releasing hormone (CRH) system (for reviews see [6,9,10,13–20]).”
BackgroundCaldarone, B. J., Karthigeyan, K., Harrist, A., Hunsberger, J. G., Wittmack, E., King, S. L., Jatlow, P., & Picciotto, M. R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1518-7 · Cited by 76
“Although it is well established that antidepressants are effective only following chronic treatment in humans (Wong and Licinio 2001), this time course has been difficult to reproduce in rodent models of depression in which antidepressant-like responses are often seen following acute injection…”
BackgroundInfluentialSakurai, M., Yamamoto, Y., Kanayama, N., Hasegawa, M., Mouri, A., Takemura, M., Matsunami, H., Miyauchi, T., Tokura, T., Kimura, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58806-w · Cited by 81
Irie, Y., Itokazu, N., Anjiki, N., Ishige, A., Watanabe, K., & Keung, W. M. (2004) · Brain Research · doi:10.1016/j.brainres.2004.03.040 · Cited by 81
Sex-Specific Neurotoxic Effects of Organophosphate Pesticides Across the Life Course
Comfort, N. T., & Ré, D. B. (2017) · Current Environmental Health Reports · doi:10.1007/s40572-017-0171-y · Cited by 78
Ten-Eleven Translocation Proteins Modulate the Response to Environmental Stress in Mice
Cheng, Y., Sun, M., Chen, L., Li, Y., Lin, L., Yao, B., Li, Z., Wang, Z., Chen, J. C., Miao, Z., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.061 · Cited by 76
“Depression is a mental disorder characterized by a pervasive and persistent low mood, which is usually accompanied by a loss of interest in activities once pleasurable (Wong and Licinio, 2001).”
BackgroundEffect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of Venlafaxine
McAlpine, D. E., Biernacka, J. M., Mrazek, D. A., O’Kane, D. J., Stevens, S. R., Langman, L. J., Courson, V. L., Bhagia, J., & Moyer, T. P. (2010) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181fcf94d · Cited by 75
“Depression is a recurrent and life-threatening mental illness with a high incidence in the population, representing a major social and economic burden.(1) Venlafaxine (V), a serotonin (5-hydroxytryptamine) and norepinephrine reuptake inhibitor,(2) became available for treatment of depression in the United States in 19…”
BackgroundWang, C., Guo, J., & Guo, R. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1543-9 · Cited by 77
“Background Depression is a mental disorder characterized by a pervasive low mood and loss of pleasure or interest in usual activities [1] and is the most common psychiatric illness that involves the disturbance of mood, with 10 to 20% lifetime prevalence [2].”
BackgroundDepression and Metabolic Syndrome: A Narrative Review
Al-Khatib, Y., Akhtar, M. A., Kanawati, M. A., Mucheke, R., Mahfouz, M., & Al-Nufoury, M. (2022) · Cureus · doi:10.7759/cureus.22153 · Cited by 89
“The course of depression is recurrent as patients go through periods of symptomatic episodes and periods of recovery [1].”
BackgroundMonoaminergic agents modulate antidepressant-like effect caused by diphenyl diselenide in rats
Savegnago, L., Jessé, C. R., Pinto, L. G., da Rocha, J. B. T., Nogueira, C. W., & Zeni, G. R. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.05.006 · Cited by 79
Chiou, S., Ku, H., Tsai, T., Lin, H., Chen, L., Chien, C., Ho, L. L. ‐., Lee, C., & Chang, Y. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706766 · Cited by 74
“Depression is one the most common psychiatric disorders, with 10–20% lifetime prevalence (Gurvits et al., 1996; Wong & Licinio, 2001).”
BackgroundFolic acid prevents depressive-like behavior induced by chronic corticosterone treatment in mice
da Rosa, P. B., Ribeiro, C. M., Bettio, L. E. B., Colla, A. R. D. S., Lieberknecht, V., Moretti, M., & Rodrigues, A. L. S. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.10.003 · Cited by 80
The effect of high-fat diet on rat’s mood, feeding behavior and response to stress
Aslani, S., Vieira, N., Marques, F., Costa, P. S., Sousa, N., & Palha, J. A. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.178 · Cited by 69
Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress
Dagytė, G., Crescente, I., Postema, F., Seguin, L., Gabriel, C., Mocaër, E., Boer, J. A. D., & Koolhaas, J. M. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.045 · Cited by 69
“Currently, most of depressed patients are treated with monoaminergic compounds, such as selective serotonin reuptake inhibitors (SSRI), serotonin and noradrenaline reuptake inhibitors (SNRI), and noradrenaline reuptake inhibitors (NRI), which potentiate the brain’s monoaminergic system and elevate the monoamine levels…”
Freitas, A. E., Machado, D. G., Budni, J., Neis, V. B., Balen, G. O., Lopes, M. W., de Souza, L. F., Dafré, A. L., Leal, R. B., & Rodrigues, A. L. S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.035 · Cited by 78
Theory of active antidepressants: A nonsynaptic approach to the treatment of depression
Kiss, J. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.006 · Cited by 82
Felice, D., O’Leary, O. F., Pizzo, R., & Cryan, J. F. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.066 · Cited by 78
Animal model and neurobiology of suicide
Preti, A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.027 · Cited by 72
“A central tenet of many animal models is that depression is a maladaptive response to stress (Wong and Licinio, 2001; Duman, 2010).”
BackgroundSubba, R., Sandhir, R., Singh, S. P., Mallick, B. N., & Mondal, A. C. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15136 · Cited by 75
“Its manifestation is characterized by symptoms such as fatigue, abnormal appetite, sleep disturbances, cognitive impairment, poor concentration, pessimism, low self- esteem, persistent suicidal ideation, among many other symptoms (Wong & Licinio, 2001).”
BackgroundMicroglial NLRP3 inflammasome-mediated neuroinflammation and therapeutic strategies in depression
Han, Q.-Q., Li, W., Chen, P., Wang, L., Bao, X., Huang, R., Liu, G., & Chen, X. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.390964 · Cited by 75
“…behind the pathogenesis of depression are not well understood, there have been a number of hypotheses put forward, such as the monoamine hypothesis (Wong and Licinio, 2001), neurotrophic hypothesis (Duman, 2005), inflammatory hypothesis (Miller and Raison, 2016), stress-diathesis model (Kendler…”
BackgroundPiperine reverses the effects of corticosterone on behavior and hippocampal BDNF expression in mice
Mao, Q., Huang, Z., Zhong, X., Xian, Y., & Ip, S. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.04.017 · Cited by 69
Xi, G., Hui, J., Zhang, Z., Liu, S., Zhang, X., Teng, G., Chan, K. C., Wu, E. X., Nie, B., Shan, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028686 · Cited by 65
“Depression, with 10 to 20% lifetime prevalence, is the most common psychiatric illness that involves the disturbance of mood [1].”
Dhingra, D., & Chhillar, R. (2012) · Pharmacological Reports · doi:10.1016/s1734-1140(12)70875-7 · Cited by 71
“Selective serotonin reuptake inhibitors and noradrenaline reuptake inhibitors are effective in treating most depressive episodes, but about one third of these patients show only partial or no response to the treatment [40].”
BackgroundMoretti, M., Freitas, A. E., Budni, J., Fernandes, S. C. P., Balen, G. O., & Rodrigues, A. L. S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.07.024 · Cited by 72
Lobato, K. R., Cardoso, C. C., Binfaré, R. W., Budni, J., Wagner, C. L. R., Brocardo, P. S., de Souza, L. F., Brocardo, C., Flesch, S., Freitas, A. E., et al. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.02.002 · Cited by 67
Agmatine produces antidepressant-like effects by activating AMPA receptors and mTOR signaling
Neis, V. B., Moretti, M., Bettio, L. E. B., Ribeiro, C. M., da Rosa, P. B., Gonçalves, F. M., Lopes, M. W., Leal, R. B., & Rodrigues, A. L. S. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.009 · Cited by 71
“Taking into account that several studies have shown that the prevalence of depression is about two fold higher in women than in men (Wong and Licinio, 2001), this study was performed using adult female Swiss mice (30–35 g), from the Central Biotery of the Federal University of Santa Catarina.”
MethodUmukoro, S., Kalejaye, H. A., Ben-Azu, B., & Ajayi, A. M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.016 · Cited by 66
Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models
Tian, S., Laudon, M., Han, L., Gao, J., Huang, F., Yang, Y., & Deng, H. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.80 · Cited by 71
Jin, Y., Meng, Q., Mei, L., Zhou, W., Zhu, X., Mao, Y., Xie, W., Zhang, X., Luo, M., Tao, W., et al. (2019) · Pain · doi:10.1097/j.pain.0000000000001724 · Cited by 70
“antianxiety drug action; however, approximately one-third of anxiety patients do not respond well to treatment.(8,20,46,50) The”
BackgroundIgnácio, Z. M., Réus, G. Z., Abelaira, H. M., & Quevedo, J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.06.036 · Cited by 65
Mocaër, E., Dagytė, G., Crescente, I., Postema, F., Seguin, L., Gabriel, C., den Boer, J. A., & Koolhaas, J. M. (2011) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(11)70669-1 · Cited by 65
Antidepressant-like effects of Tagetes lucida Cav. in the forced swimming test
Guadarrama-Cruz, G., Alarcón-Aguilar, F. J., Lezama-Velasco, R., Vázquez-Palacios, G., & Bonilla‐Jaime, H. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.08.013 · Cited by 71
Liu, J., Qiao, W., Yang, Y., Ren, L., Sun, Y., & Wang, S. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.02.026 · Cited by 66
Borsotto, M., Veyssiere, J., Moha ou Maati, H., Devader, C., Mazella, J., & Heurteaux, C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12953 · Cited by 63
“All current ADs also have a slow onset of action, which may take several weeks to months to produce a therapeutic response and are only moderately effective, leaving more than one-third of depressed individuals resistant to drug treatments (Wong and Licinio, 2001).”
BackgroundThe PHF21B gene is associated with major depression and modulates the stress response
Wong, M., Arcos‐Burgos, M., Liu, S., Velez, J. I., Yu, C., Baune, B. T., Jawahar, M. C., Arolt, V., Dannlowski, U., Chuah, A., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.174 · Cited by 67
“Pathway and Network Analyses MDD associated genes in the Mexican-American cohort were overrepresented in the following GO processes: (1) natural immune response (granuloma formation, natural killer cell degranulation, synaptic vesicle priming, natural killer cell activation, germinal center formation), (2) G protein c…”
Self-citationSerotonin and the Evaluation of Future Rewards: Theory, Experiments, and Possible Neural Mechanisms
SCHWEIGHOFER, N., TANAKA, S. C., & DOYA, K. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1390.011 · Cited by 61
“� kr (t + k) � , ( 5 ) where r(t), r(t + 1), r(t + 2) ... are the rewards acquired by following a certain action policy P(a}s) starting from the state s(t), and � is a discount factor such that 0 � <1. We note here that this formulation of the value function reduces to that of the exponential value of a single reward…”
BackgroundMorphological Brain Changes in Depression: Can Antidepressants Reverse Them?
Miguel-Hidalgo, J. J., & Rajkowska, G. (2002) · CNS Drugs · doi:10.2165/00023210-200216060-00001 · Cited by 64
“[1,2] Alterations in the synaptic availability of”
Dhingra, D., Joshi, P., Gupta, A. K. D., & Chhillar, R. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00256.x · Cited by 63
“Furthermore, about one-third of these patients show only partial or no response to the treatment [3].”
BackgroundCassani, J., Dorantes‐Barrón, A. M., Mayagoitia-Novales, L., Real, G. A., & Estrada‐Reyes, R. (2014) · Molecules · doi:10.3390/molecules191221442 · Cited by 67
“Depression and anxiety disorders represent the second most common health problems worldwide [1–4].”
BackgroundLiu, Q., Li, B., Zhu, H., Wang, Y.-Q., Yu, J. M., & Wu, G.-C. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.07.007 · Cited by 71
“Although significant progress has been made in treating depression, about 20–30% of depressed patients are resistant to current drug therapies and there is a 2–3 week lag of onset to therapeutic efficacy (Duman et al., 2000; Wong and Licinio, 2001).”
BackgroundBrain organic cation transporter 2 controls response and vulnerability to stress and GSK3β signaling
Couroussé, T., Bacq, A., Belzung, C., Guiard, B. P., Balasse, L., Louis, F., Guisquet, A.-M. L., Gardier, A. M., Schinkel, A. H., Giros, B., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.86 · Cited by 63
Therapeutic potential of agmatine for CNS disorders
Neis, V. B., da Rosa, P. B., Olescowicz, G., & Rodrigues, A. L. S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.05.006 · Cited by 65
“order with a high prevalence (about 17% in the lifetime) in the population around the world (Wong and Licinio, 2001).”
Hui, J., Zhang, J., Pu, M., Zhou, X., Dong, L., Mao, X., Shi, G., Zou, J., Wu, J., Jiang, D., et al. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy040 · Cited by 60
“Depression, with 10% to 20% lifetime prevalence, is one of the most common psychiatric illness that involves the disturbance of mood (Wong and Licinio, 2001).”
BackgroundInduced depressive behavior impairs learning and memory in rats
Sun, M., & Alkon, D. L. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.07.041 · Cited by 64
Bjørnebekk, A., Mathé, A. A., & Brené, S. (2010) · Hippocampus · doi:10.1002/hipo.20683 · Cited by 61
“(Blumenthal et al., 1999; Babyak et al., 2000; Wong and Licinio, 2001), decreases immobility in the Porsolt”
BackgroundSerotonin transporter gene methylation is associated with hippocampal gray matter volume
Dannlowski, U., Kugel, H., Redlich, R., Halik, A., Schneider, I., Opel, N., Grotegerd, D., Schwarte, K., Schettler, C., Ambrée, O., et al. (2014) · Human Brain Mapping · doi:10.1002/hbm.22555 · Cited by 56
“Altered serotonergic neurotransmission appears to play a pivotal role in the etiology of psychiatric disorders such as major depression, one of the most debilitating disorders worldwide [Wong and Licinio, 2001].”
BackgroundChandrasekhar, Y., Ramya, E. M., Navya, K., Kumar, G. P., & Anilakumar, K. R. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.031 · Cited by 67
Sex Differences in Depression and Anxiety
Pavlidi, P., Kokras, N., & Dalla, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_375 · Cited by 63
Metadata
- Authors
- Wong, M.-L., & Licinio, J.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Wong, Ma-Li
- Venue
- Nature Reviews Neuroscience
- Published
- 2001-05
- Volume
- 2
- Issue
- 5
- Pages
- 343-351
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2102343823
- Cited by
- 656
- References
- 104
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 16 · 2023: 22 · 2022: 18 · 2021: 22 · 2020: 14 · 2019: 20 · 2018: 33 · 2017: 29 · 2016: 28 · 2015: 24 · 2014: 39 · 2013: 30 · 2012: 41
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, antidepressant targets, genetic susceptibility, environmental factors, animal models of depression, cognitive impairment, depression classification, genomic tools, therapeutic outcome prediction
- MeSH terms
- Animals, Antidepressive Agents, Brain Chemistry, Depression, Humans, Drug Design, Causality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.